Retatrutide Liver Fat Reduction Percentage Clinical Trial Results

Retatrutide liver fat reduction percentage clinical trial results from Phase 2 trials show dramatic effects in patients with non-alcoholic fatty liver disease (NAFLD).[1][2][3] Higher doses achieved up to 86% mean liver fat reduction at 48 weeks, with over 90% of participants reaching normal liver fat levels below 5%.[2][3] These findings highlight retatrutide's potential as a breakthrough therapy designation for retatrutide for obesity-related liver conditions.

Introduction to Retatrutide Liver Fat Reduction Percentage Clinical Trial Results

Retatrutide is an investigational drug developed by Eli Lilly.[1][3] It acts as a triple agonist, targeting GIP, GLP-1, and glucagon receptors to improve metabolism.[3]

What is Retatrutide? Triple Agonist Mechanism for NAFLD

Retatrutide mimics three key hormones: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.[3] This unique triple action helps reduce appetite, boost energy use, and lower fat storage in the liver.[3]

In NAFLD, excess fat builds up in liver cells, often linked to obesity. Retatrutide's glucagon component may directly target liver fat by promoting fat breakdown.[3] Early data suggest it could reverse fatty liver changes [1].

Why Liver Fat Reduction Matters in Obesity and NAFLD/NASH

NAFLD affects up to 30% of adults worldwide and often progresses to NASH, fibrosis, or cirrhosis. Reducing liver fat by over 30% can resolve NAFLD and prevent serious damage.

Obesity drives this process through insulin resistance and poor lipid metabolism. Treatments like retatrutide address root causes, offering hope beyond lifestyle changes alone. For patients, this means lower risks of diabetes and heart disease.

Overview of Phase 2 Clinical Trials and Key Findings

Phase 2 trials tested retatrutide in obese adults, including a NAFLD substudy with 98 participants.[1] Key results showed dose-dependent liver fat drops, with highest doses exceeding 80% reduction versus placebo.[2][3]

Presented at ADA 2023, these retatrutide liver fat reduction percentage clinical trial results exceeded expectations [2]. Normalization rates hit 93% on top doses, signaling strong efficacy.[2][3]

Retatrutide Clinical Trial Design and NAFLD Substudy Details

The trials followed rigorous standards to measure liver fat accurately.

Phase 2 Trial Overview: NCT04881760 and NAFLD Substudy (n=98)

NCT04881760 was a randomized, double-blind, placebo-controlled study in obesity.[1] The NAFLD substudy enrolled patients with at least 10% liver fat, confirmed by MRI.[1]

This design ensured reliable retatrutide liver fat reduction percentage clinical trial results. Participants received weekly injections for up to 48 weeks.[1]

Doses Tested: 1mg, 4mg, 8mg, 12mg vs Placebo

Doses started low and escalated to find the best balance of efficacy and retatrutide safety profile from Phase 3 trials.[3] Placebo controlled for natural changes in liver fat.[1]

Higher doses (8mg and 12mg) drove the most impressive reductions.[2][3] All active doses outperformed placebo significantly.[1][2][3]

Endpoints: Primary (24 Weeks) and Extended (48 Weeks) Liver Fat Changes

Primary endpoint was percent change in liver fat at 24 weeks via MRI-PDFF.[1] Secondary included 48-week changes and normalization rates.[1]

These endpoints captured both short-term and sustained effects. Results showed most reductions happened early, within 24 weeks.[2]

Patient Population: Obese Adults with ≥10% Baseline Liver Fat

Participants had BMI over 30 and metabolic issues common in NAFLD.[1] Exclusion criteria avoided confounding factors like alcohol use.

This group mirrors real-world patients needing liver fat treatments. Baseline liver fat averaged 15-20%, providing clear room for improvement.

Retatrutide Liver Fat Reduction Percentages at 24 Weeks

At 24 weeks, retatrutide showed rapid, dose-dependent liver fat loss.[2][3]

Dose-by-Dose Breakdown: -42.9% (1mg) to -82.4% (12mg)

Here's the breakdown from the Phase 2 NAFLD substudy:

Dose	Relative Reduction	P-value vs Placebo	Normalization Rate (<5% Liver Fat)
1mg	-42.9%	<0.001	27%
4mg	-57.0%	<0.001	52%
8mg	-81.4%	<0.001	79%
12mg	-82.4%	<0.001	86%
Placebo	+0.3%	-	0%

These retatrutide liver fat reduction percentage clinical trial results prove superior efficacy across doses [3].

Statistical Significance vs Placebo (P<0.001 All Doses)

Every dose beat placebo with high confidence (P<0.001).[1][2][3] This rules out chance and supports retatrutide's mechanism.

Liver fat increased slightly on placebo, highlighting disease progression without treatment.[1]

Early Reductions: Most Changes Within First 24 Weeks

Over 70-80% of total reduction occurred by week 24.[2] This quick action could benefit patients needing fast relief.

Sustained dosing maintained gains through week 48.[2]

Retatrutide Liver Fat Reduction Percentages at 48 Weeks

Longer-term data confirmed even greater benefits.[2][3]

Impressive 48-Week Results: >80% Mean Reduction (8mg/12mg)

At 48 weeks, higher doses sustained deep reductions. Mean changes exceeded 80% for 8mg and 12mg groups.[2][3]

Placebo showed minimal shift (-4.6%), emphasizing retatrutide's impact.[1]

-81.7% (8mg) and -86% (12mg) Relative Reductions

• 8mg: -81.7% mean reduction[2][3]
• 12mg: -86.0% mean reduction[2][3]

Over 80% of participants on these doses hit ≥70% reduction thresholds.[2] These retatrutide liver fat reduction percentage clinical trial results position it as a leader in NAFLD therapy.

≥70% Reduction Achieved by 80%+ Participants on Higher Doses

High response rates: 80-90% achieved major milestones.[2][3] This consistency across patients is rare in liver trials.

Liver Fat Normalization Rates with Retatrutide

Normalization means liver fat below 5%, resolving NAFLD.

89% Normalization (<5% Liver Fat) at 8mg; 93% at 12mg

• 8mg: 89% normalized at 48 weeks[2][3]
• 12mg: 93% normalized[2][3]

Over 85% of treated patients shed the "fatty liver" label.[2]

>90% Resolution in NAFLD Subset; 9/10 Patients Normalized

In the full substudy, 9 out of 10 on high doses normalized.[2] This near-complete resolution is groundbreaking.

>85% No Longer Classified as Fatty Liver

Regulatory definitions often require ≥30% reduction for response. Retatrutide far surpassed this in most cases.[2]

Associated Benefits: Weight Loss and Glycemic Control

Liver improvements tied to broader metabolic gains.

Weight Loss: 23.8% (8mg), 25.9% (12mg) at 48 Weeks

Patients lost 23.8% body weight on 8mg and 25.9% on 12mg.[3] All on high doses lost at least 5%.[3]

Liver fat drops correlated strongly with weight loss.[3] See extended data in the Triumph-1 trial weight loss results.

HbA1c Reductions: 1.3-2.0%; 82% Achieved <6.5% in T2D

In type 2 diabetes subsets, HbA1c fell 1.3-2.0%.[3] Up to 82% reached <6.5%, 31% <5.7%.[3]

These gains improved insulin sensitivity, aiding liver health.

Correlations: Liver Fat Tied to Weight, Insulin Sensitivity, Lipids

Reductions linked to less abdominal fat and better lipids.[3] This multi-target effect boosts overall outcomes.

Safety Data and Side Effects in Retatrutide Trials

Retatrutide was generally well-tolerated.[1][3]

Safety Profile: Similar to GLP-1 Agonists, Well-Tolerated

No new signals beyond class effects like nausea.[3] Discontinuation rates were low, comparable to semaglutide.[3]

Detailed retatrutide safety profile from Phase 3 trials supports long-term use.

Common Side Effects: GI-Related (Class Effects), No Unique Signals

Gastrointestinal issues (nausea, vomiting, diarrhea) were most common, mild to moderate.[3] They decreased over time.

Learn more about retatrutide dysesthesia side effects, a noted but manageable issue.

Discontinuation Rates and NAFLD-Specific Tolerability

Rates were dose-dependent but under 10% for high doses.[3] NAFLD patients tolerated it well, with no liver-related worsening.[1]

Current Clinical Trial Status and FDA Approval Outlook

Progress continues post-Phase 2.[4]

Phase 2 Completed: ADA 2023 Presentation, Publications Pending

Data from ADA 2023 and journals confirm results.[2][3] Full NAFLD substudy publication expected soon. These Phase 2 retatrutide liver fat reduction percentage clinical trial results support ongoing development.[1][4]

Legal Status: Investigational, No FDA Approval Yet

Retatrutide remains investigational worldwide.[1][3] Not available outside trials.

Path to Phase 3 and Potential for NAFLD/NASH Indications

Phase 3 trials (TRIUMPH program) are enrolling for obesity and related conditions.[4] Strong Phase 2 data may earn breakthrough therapy designation for retatrutide.[4]

Track updates via retatrutide NDA submission and FDA PDUFA timeline, including Phase 3 progress.[4]

Implications for NAFLD/NASH Treatment and Future Research

These results could transform care.

Potential to Reverse Early NAFLD, Prevent NASH Progression

Up to 93% normalization suggests reversal of early disease.[2][3] This "bottom-up" approach may halt progression to NASH. The retatrutide liver fat reduction percentage clinical trial results underscore this potential.[2]

Role of Glucagon Agonism in Enhanced Efficacy

Glucagon adds liver-specific fat burning, outperforming dual agonists.[3] See retatrutide vs tirzepatide comparison for context.

Comparisons to Other Therapies and Unmet Needs

Current options lack strong liver data. Retatrutide fills gaps in obesity-driven NAFLD.

Conclusion: Retatrutide's Promising Liver Fat Results

Key Takeaways on Reduction Percentages and Normalization

Retatrutide liver fat reduction percentage clinical trial results: 86% at 12mg/48 weeks, 93% normalization.[2][3] Weight loss and glycemic benefits add value.[3]

What to Watch: Phase 3 Trials and Approval Timeline

Phase 3 outcomes will confirm durability.[4] Approval could come by 2027, revolutionizing NAFLD treatment.[4]

References

1. ClinicalTrials.gov (NCT04881760)
2. ADA 2023 Abstract
3. NEJM Publication (Phase 2 Trial)
4. ClinicalTrials.gov TRIUMPH-1 (Phase 3 Trial)